Abstract
Background We aimed to quantify the extent to which the effect of antihypertensive drugs on incident heart failure (HF) is mediated by their effect on kidney function. We hypothesized that the dynamic change in kidney function is the mechanism behind differences in the rate of incident HF in ALLHAT participants randomized to lisinopril, amlodipine, and doxazosin, in comparison to those randomized to chlorthalidone.
Methods Causal mediation analysis of ALLHAT data (1994-2002) included participants with available baseline and 24-48 month estimated glomerular filtration rate (eGFR) (n=27,918; mean age 66±7.4; 32.4% black, 56.3% men). Change in eGFR was the mediator. Incident symptomatic HF was the primary outcome. Hospitalized/fatal HF was the secondary outcome. Linear regression (for mediator) and logistic regression (for outcome) analyses were adjusted for demographics, cardiovascular disease, and risk factors.
Results There were 1,769 incident HF events, including 1,359 hospitalized/fatal HF events. In fully adjusted causal mediation analysis, the relative change in eGFR mediated 38% of the effect of amlodipine, 25.5% of doxazosin, and 6.3% of lisinopril on incident symptomatic HF, and 42% of the effect of amlodipine, 55.3% of doxazosin, and 12.7% of lisinopril on hospitalized/fatal HF. In lisinopril arm, eGFR changes had an opposite effect on symptomatic versus hospitalized/fatal HF outcomes. Reduction in eGFR by at least 40% explained > 50% of increased risk in hospitalized/fatal HF but 18-25% reduction of symptomatic HF risk.
Conclusion On the risk difference scale, change in eGFR accounts for more than 50% of the mechanism by which antihypertensive medications affect HF.
Clinical Trial Registration URL:www.clinicaltrials.gov Unique identifier: NCT00000542.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT00000542
Funding Statement
This work was partially supported by HL118277 (Tereshchenko). The ALLHAT study was supported by the National Heart, Lung, and Blood Institute (NO1-HC-35130). ALLHAT investigators received contributions of study medications supplied by Pfizer (amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), Bristol-Myers Squibb (pravastatin), and financial support provided by Pfizer.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Oregon Health & Science University Institutional Review Board reviewed the study and determined the deidentified nature of the publicly available dataset.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We used the ALLHAT dataset that is publicly available from the National Heart, Lung, and Blood Institute, via BioLINCC.
